Limited success and high attrition in the 9-month all-oral regimen for MDR-TB: Evidence from a tertiary care setting in Indonesia
{{output}}
Background: The WHO endorses the 9-month all-oral regimen for MDR-TB as a preferred therapeutic option due to its shorter duration, lower cost, and improved adherence compared to the 18-24-month more extended longer regimen. Whil... ...
